Titan Pharmaceuticals Inc
TTNPDelisted Oct 2, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000910267
Titan Pharmaceuticals Inc was delisted on Oct 2, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 18 institutions reported holding it in 13F filings for Q3 2025, worth $107.1K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 18
- Q3 2025, −2 vs. previous quarter
- 13F value
- $107.1K
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding TTNP, Q3 2025
No superinvestor reported holding TTNP at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by Titan Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 28, 2023 (view filing)4:14 PM ET | Jun 21 | 7 days | Lazar David E. and 1 otherChief Executive Officer | SSaleCommon Stock, par value $0.001 | −3.39M | $1.23 | −$4.17M | −100.0%0 after | Amended |
| Jun 28, 2023 (view filing)4:14 PM ET | Jun 21 | 7 days | Lazar David E. and 1 otherChief Executive Officer | SSaleCommon Stock, par value $0.001 | −359.1K | $1.23 | −$441.7K | −100.0%0 after | Amended |
| Jan 26, 2023 (view filing)1:05 PM ET | Jan 24-25 | 2 days | Lazar David E. and 1 otherChief Executive Officer | PPurchaseCommon Stock, par value $0.001 | +57.5K | $0.9789 | +$56.3K | +1.7%3.39M after | 2 lots |
| Jul 8, 2022 (view filing)6:00 PM ET | Jul 6-7 | 2 days | Activist Investing LLC and 1 otherOther: Member of 10% owner group | PPurchaseCommon Stock, par value $0.001 | +1.91M | $0.859 | +$1.64M | +134.4%3.33M after | 2 lots |
| Jul 8, 2022 (view filing)6:00 PM ET | Jul 6 | 2 days | Activist Investing LLC and 1 otherOther: Member of 10% owner group | PPurchaseCommon Stock, par value $0.001 | +315.9K | $0.8926 | +$282.0K | +732.2%359.1K after |
Top 10 13F holders, Q3 2025
The largest institutional positions in Titan Pharmaceuticals Inc at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DRW Securities, LLC | 21,267 | $101.9K | 0.01% | +21,267 | New |
| UBS Group AG | 480 | $2.30K | 0.00% | −2,947−86.0% | Reduced |
| Tower Research Capital LLC (TRC) | 469 | $2.25K | 0.00% | +469 | New |
| CoreCap Advisors, LLC | 88 | $422 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 19 | $91 | 0.00% | +1+5.6% | Added |
| Group One Trading, L.P. | 12 | $58 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 10 | $35 | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 6 | $29 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 2 | $10 | 0.00% | 00.0% | Unchanged |
| Global Wealth Strategies & Associates | 2 | $10 | 0.00% | 00.0% | Unchanged |